Stroke: development, prevention and treatment with peptidase inhibitors.
Stroke is the leading cause of long-term disability in the United States and affects more people than any other neurologic disorder. Hypertension is a major risk factor associated with stroke. Several anti-hypertensive agents have been used to treat chronic hypertension to reduce the morbidity and mortality of stroke. Previous experimental studies have shown reduced stroke mortality with angiotensin-converting enzyme (ACE) inhibitors. This review discusses the development of stroke and potential use of ACE inhibitors in prevention and treatment of this disease. Furthermore, this review focuses on current investigations aimed at cellular mechanisms involved in stroke-induced microvascular alterations.
Mark
K S
KS
Department of Pharmacology, University of Arizona College of Medicine, Tucson, AZ 85724-5050, USA.
Davis
T P
TP
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012084:Renin-Angiotensin System; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology
D000959:Antihypertensive Agents; D004791:Enzyme Inhibitors; D011480:Protease Inhibitors; D007703:Peptidyl-Dipeptidase A